Public-registry trials using Equecabtagene Autoleucel Injection (Eque-cel) that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy | Nanjing IASO Biotechnology Co., Ltd. | Refractory Immune-mediated Necrotizing Myopathy | PHASE1 / PHASE2 | 4 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →